Overview

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double blind, placebo-controlled study evaluating the effects of placebo, codeine, methylnaltrexone and codeine with methylnaltrexone on gastrointestinal motility and colonic transit of solids in healthy human subjects. The hypotheses are: 1. Methylnaltrexone administered subcutaneously enhances gastrointestinal motility with acceleration of overall colonic transit, and ascending colon emptying of solids in healthy humans. 2. Methylnaltrexone significantly accelerates colonic transit that is delayed by codeine
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Codeine
Methylnaltrexone
Naltrexone